Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation
Puntos clave
Letermovir shows improved efficacy in preventing cytomegalovirus infection post-transplantation.
In this study, lettermovir treatment reduced CMV reactivation rates by 30% compared to high-dose valacyclovir.
Analysis of allogeneic hematopoietic stem cell transplant patients indicates significant differences in medication outcomes.
Understanding these treatment differences highlights the need for tailored prophylactic strategies.
Me gusta
Guardar
Compartir
Me gusta
Guardar
Compartir
Comparison of Letermovir Versus High-Dose Valacyclovir for Cytomegalovirus Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation | Synapse